An Insulin Receptor Mutant (Asp\textsuperscript{707} → Ala), Involved in Leprechaunism, Is Processed and Transferred to the Cell Surface but Unable to Bind Insulin*

Leen M. ’t Hart, Dick Lindhout, Gerard C. M. Van der Zont, Hülya Kayserilili, Memnune Y. Apak, Wim J. Kleijer, Eric R. Van der Vorm, and J. Antonie Maassen**

From the †Department of Medical Biochemistry, Leiden University, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands, ‡Department of Clinical Genetics, University Hospital, Erasmus University, 3015GE Rotterdam, The Netherlands, ¶Institute of Child Health, Medical Genetics Unit, University of Istanbul, 34390 Istanbul, Turkey, and ⎯Juliana Childrens Hospital, 2566E R The Hague, The Netherlands

We have recently encountered leprechaun patient HO. This patient was found to have a mutation in the insulin receptor which interferes with insulin binding, probably by a direct effect on the structure of the insulin binding site.

Insulin induces mitogenic and metabolic responses in cells. In addition, in muscle and adipose tissues, glucose transporters become translocated to the plasma membrane (1). These responses require tyrosine kinase activity in the cytoplasmic tail of the insulin receptor, which is activated on binding of insulin (2, 3). The insulin receptor is synthesized as a proreceptor, and after proteolytic cleavage into α and β subunits and extensive glycosylation in the Golgi apparatus, appears as a tetrameric complex (4). The insulin receptor is synthesized as a proreceptor, which after proteolytic cleavage into α and β subunits and extensive glycosylation in the Golgi apparatus, appears as a tetrameric complex (4).

A number of naturally occurring mutations in the insulin receptor have been found to associate with diseases of severe insulin resistance (5). Missense mutations in the cytoplasmic domain of the receptor are often seen in patients with type A insulin resistance. These mutant receptors are processed to αβ\textsubscript{2} tetramers and transported to the cell surface. Usually they retain their insulin binding properties. The impaired activation of the receptor tyrosine kinase contributes to the development of the syndrome of insulin resistance. Missense mutations in the homozygous or compound heterozygous state in the extracellular part of the receptor are often associated with syndromes of extreme insulin resistance such as leprechaunism (MIM 246200) or Rabson Mendenhall syndrome (MIM 262190) (5, 6). Many of the missense mutations involved lead to a loss of high affinity insulin binding sites on cells. These mutations are predicted to affect the folding of the α subunit and the formation of correct disulfide bonds. As a result, the proreceptor is retained in the endoplasmic reticulum, and no receptors are transported to the cell surface (7, 8).

Another situation that leads to a decreased number of functional receptors on the cell surface is represented by the naturally occurring mutation Glu\textsuperscript{460}. This receptor undergoes enhanced internalization and degradation on binding of insulin (9).

We have recently encountered leprechaun patient HO. This patient was found to have a mutation in the insulin receptor, which interferes with insulin binding, probably by a direct effect on the structure of the insulin binding site.

EXPERIMENTAL PROCEDURES

Reagents, Antibodies, and General Procedures—Cultures of fibroblasts and CHO cell lines were as described (7). Taq polymerase was from Perkin-Elmer; other enzymes for DNA manipulation were from New England Biolabs, Promega, and Boehringer Mannheim. Other reagents were of analytical grade. Monodiodo-A\textsubscript{125} insulin (2000 Ci/mm), a monoclonal antibody against the insulin receptor and biotin succinimidyl ester were from Amersham Corp. Protein A-Sepharose and wheat germ agglutinin-Sepharose were from Pharmacia Biotech, Inc. Disuccinimidyl suberate was from Pierce. Preparation of polyclonal antibodies against the insulin receptor, isolation of DNA from cultured fibroblasts, and amplification of the coding parts of exons 1–22 of the insulin receptor were described previously (7). Monoclonal antiphosphotyrosine antibody (PY20) was from Upstate Biotechnology, Inc. Glycoprotein from CHO cells was isolated by chromatography on wheat germ agglutinin-Sepharose, as described previously, using Hepes-containing buffers instead of Tris. Protein content was determined using the BioRad DC protein assay kit.

*This work was supported by grants from the Diabetes Fonds Nederland and the Netherlands Organization for the Advancement of Pure Research through the foundation of Medical Research (NWO-Medische Wetenschappen). Additional support was provided by the European Union Cost B5 program. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**To whom correspondence should be addressed: Dept. of Medical Biochemistry, Sylvius Laboratory, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands. Tel.: 31-71-527-6127; Fax: 31-71-527-6125.

The abbreviations used are: CHO, Chinese hamster ovary; IR, insulin receptor; WT, wild type; ECL, enhanced chemiluminescence.
Patient—The child, a boy, was born from first cousin parents. He had the phenotypic characteristics of leprechaunism, including marked lack of adipose tissues, prominent eyes and lips, wrinkled loose skin, acanthosis nigricans, abdominal distention, prominent nipples, and large phalii. Insulin levels varied during the day between 237 and 424 milliunits/liter (normal value, <25 milliunits/liter). The child died at the age of 8 months.

DNA Sequencing—The exons for the insulin receptor gene were amplified using DNA from the patient's fibroblasts (10). Amplified fragments were purified on low melting point agarose and sequenced using the DNA sequencing kit from Pharmacia as described previously (7).

Construction of Insulin Receptor (Ala707) DNA in the Expression Vector SV40HIR—A DNA fragment containing exon 10 was prepared by polymerase chain reaction from the patient's DNA (10). This fragment was digested by DraII and BamHI and ligated into a plasmid (pMK5) containing the BamHI-Hindll fragment of the human IR (nucleotides 1926–3187; numbering according to Ref. 2). An Xhol-Xhol fragment (nucleotides 2091–3068) was isolated and exchanged for the corresponding Xhol-Xhol fragment in the WT IR cDNA, cloned in the pUC12 vector. A BstEI-BstEII fragment (nucleotides 1836–4321) was exchanged for the corresponding fragment in the expression vector carrying the WT IR cDNA, driven by the SV40 promoter (11). The correct structure of the exchanged fragment was confirmed by DNA sequencing.

Transfection of CHO Cells and Selection of Clones Expressing Ala707 IR—Construction of clonal CHO cell lines expressing mutant insulin receptors was done by using lipofectamine (Life Technologies, Inc.), EDTA, 0.1 mM phenylmethylsulfonyl fluoride, Trasylol, and soybean trypsin inhibitor; 1

RESULTS

Insulin Binding to the Patient's Fibroblasts—Insulin binding to cultured fibroblasts from leprechaun patient HO and to fibroblasts from a healthy control is visualized in Fig. 1. For comparison, results of an insulin binding experiment using fibroblasts from leprechaun G are included. Leprechaun G was described by us previously (12) and is homozygous for a mutation in the insulin receptor, changing Leu233 into Pro. High affinity insulin binding sites were nearly absent on fibroblasts from patient HO and leprechaun G. The absence of high affinity insulin binding sites is a characteristic property of fibroblasts from most patients with leprechaunism.

DNA Sequence Analysis—DNA was isolated from cultured fibroblasts of patient HO and from peripheral blood of both parents. Exons encoding the insulin receptor were amplified (10) and analyzed by DNA sequence analysis, directly on amplified DNA. Apart from known polymorphisms, the patient exhibited an additional mutation in homozygous form, which leads to replacement of the Asp codon GAT at position 707 by Ala.
An Insulin Receptor Mutant Asp$_{707}$ → Ala

Figure 2. Analysis of IR expression in transfected CHO cells by Western blot. CHO cells were transfected by cDNA encoding the WT IR, Ala$_{707}$ IR, Arg$_{31}$ IR, or expression vector alone (control). Clonal cell lines were isolated, and total cell lysate was analyzed by Western blotting using an antiseraum recognizing a peptide epitope on the carboxyl terminus of the β chain. Arrows, positions of the β subunit (95 kDa) and the proreceptor (200 kDa).

Figure 3. Analysis of IR expression in transfected CHO cells by metabolic labeling and autoradiography. CHO cells were transfected by cDNA encoding the WT or Ala$_{707}$ IR or mock transfected (control). Cells were grown in medium containing $[^{35}$S]methionine, followed by lysis of the cells and immune precipitation of the insulin receptor. The immune precipitated receptor was subjected to electrophoresis on SDS-polyacrylamide gels, and the gels were analyzed by autoradiography.

Figure 4. Biotinylation of cell surface proteins. CHO cells expressing WT or Ala$_{707}$ IR and control CHO cells were incubated with biotin succinimidyl ester. After lysing the cells, insulin receptors were immunoprecipitated by a polyclonal antibody, and the immune precipitate was subjected to Western blot analysis. Visualization of biotinylation was by streptavidin-peroxidase conjugate and ECL.

Gous for this mutation. No other mutations were detected in the coding or consensus sequences at the splice junctions. Analysis by polymerase chain reaction of cDNA prepared from the patient’s fibroblasts and from fibroblasts of a control individual indicated approximately normal levels of IR mRNA (not shown).

Expression of Ala$_{707}$ IR in CHO Cells—To examine the effect of the mutation on properties of the insulin receptor, we expressed the mutant receptor in CHO cells. IR cDNA constructs carrying the mutation were ligated into an SV40-driven expression vector carrying the neo resistance gene (11). CHO cells were transfected with the construct and, G418-resistant cell lines were selected. In addition, we transfected CHO cells by this vector carrying cDNA for the WT IR. Expression of the IR protein was monitored by Western blot analysis using a polyclonal antibody against a peptide sequence (amino acids 1330–1343) in the carboxyl-terminal region of the receptor β chain. Clonal CHO cell lines, transfected by Ala$_{707}$ IR cDNA, showed expression of the β chain. Expression levels showed some variations in different clones. Fig. 2 represents the data on a clone with an average expression level. In addition, the data in Fig. 2 include parental CHO cells and transfected CHO cells expressing WT IRs. The latter cell line expresses approximately 250,000 high affinity insulin binding sites per cell, based on Scatchard analysis. We also included in the Western blot analysis CHO cells expressing the transport-defective receptor Arg$_{31}$ IR, originating from leprechaun H (7). We showed previously that this transport-defective receptor is retained in the endoplasmic reticulum as a proreceptor and not processed into β subunits, visualized by biotinylation (Fig. 4) and iodination (Fig. 6).

Biotinylation of Cell Surface Proteins—To examine whether Ala$_{707}$ IR is transported to the surface of cells, we labeled cell surface proteins of the various CHO cell lines with biotin succinimidyl ester, a protein reagent that couples biotin moieties to exposed lysine residues of proteins on the cell surface. Parental CHO cells, and CHO cells expressing WT and Ala$_{707}$ IRs, respectively, were incubated with the reagent. Subsequently, cells were lysed, and insulin receptors were immunoprecipitated with a polyclonal antibody against the human insulin receptor. The immune precipitates were electrophoresed on SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membranes. Biotinylated proteins were visualized by peroxidase-conjugated streptavidin and ECL (Fig. 4). CHO cells expressing the WT receptor and Ala$_{707}$ IR gave a similar picture of α and β chain labeling, although when the ratio of α/β subunit labeling was considered, the mutant receptor tended to show a higher ratio of α/β chain labeling. Using parental CHO cells, no signal was obtained at these exposure times. These findings indicate that the Ala$_{707}$ mutant is transported to the cell surface to a similar extent as WT IRs.

The possibility exists that Ala$_{707}$ IR undergoes a rapid internalization and degradation on incubation with insulin. Such a situation could also deplete the cell surface of insulin receptors, thereby leading to a state of insulin resistance. This situation is exhibited by the mutant insulin receptor Glu$_{460}$ IR. This particular mutant originates from a leprechaun patient (8). As this mutation results in a decreased rate of the dissociation of the receptor-ligand complex, the presence of insulin leads to enhanced internalization and degradation. To examine whether Ala$_{707}$ IR exhibits pronounced insulin-induced receptor internalization, CHO cells expressing the mutant receptor were incubated in medium containing 1 μM insulin for up to 60 min at 37 °C, followed by biotinylation of the cell surface proteins and analysis of the mutant receptor for biotinylation. As a control, CHO cells expressing WT IRs were used. Fig. 5 shows that incubation of mutant receptor-expressing cells with insu-
Insulin does not markedly decrease the level of receptor biotinylation, indicating that a situation of enhanced insulin-induced receptor internalization does not take place. In the case of WT IR, incubation with insulin decreases the ratio of \( \alpha \) subunit labeling over \( \beta \) subunit labeling. This lower level of \( \alpha \) subunit labeling may result from binding insulin to the WT \( \alpha \) subunit, thereby reducing the number of accessible Lys residues on the subunit for biotinylation or by inducing a conformational change. The mutant receptor, which does not show insulin binding, does not exhibit a decreased ratio of \( \alpha/\beta \) subunit labeling on addition of insulin.

When \( \beta \) subunit labeling is considered in multiple experiments, an approximately 25% decrease is seen at 60 min of incubation time in the case of cells expressing WT IRs, reflecting the degree of internalization. No significant decrease is seen in the case of the receptor mutant.

Insulin Binding and Affinity Cross-linking—The various CHO clonal lines overexpressing the Ala\(^{707}\) IRs showed no increase in the level of high affinity binding of \( ^{125}\text{I}-\text{insulin} \) when compared with the parent CHO cell line (Table I). These binding experiments were performed at a tracer concentration of 30 pm \( ^{125}\text{I}-\text{moniodo-A14 insulin} \). We subsequently performed insulin binding and \( ^{125}\text{I}-\text{insulin} \)-cross-linking experiments using insulin receptors partially purified from transfected CHO cells by chromatography on wheat germ agglutinin-Sepharose. In those experiments, insulin receptors are solubilized in a Hepes buffer containing 0.1% Triton X-100. It was found that in such a buffer, \( ^{125}\text{I}-\text{insulin} \) (700 pm) in the presence of the protein cross-linker disuccinimidyl suberate was efficiently cross-linked to the \( \alpha \) subunit of both WT and Ala\(^{707}\) IR. Judged from the degree of \( \alpha \) subunit labeling, the efficiency of cross-linking seems similar (Fig. 6).

We also carried out cross-linking of \( ^{125}\text{I}-\text{insulin} \) to intact CHO cells either expressing WT or Ala\(^{707}\) IRs by disuccinimidyl suberate. Those experiments only showed labeling of the insulin receptor \( \alpha \) subunit in the case of CHO cells expressing WT IR. Cells expressing the mutant receptor showed no detectable affinity labeling of the \( \alpha \) subunit of the mutant receptor (not shown). These experiments indicate that in the case of intact cells, no transient interaction between insulin and Ala\(^{707}\) IR occurs, e.g., due to a high \( K_{off} \) rate. Only when detergent-solubilized insulin receptors were used, as present in the glycoprotein fraction, a detectable interaction between the mutant insulin receptor and insulin occurs.

Insulin-induced Autophosphorylation of Ala\(^{707}\) IR—Initially we examined whether insulin was able to induce autophosphorylation of the mutant receptor on transfected CHO cells. Cells expressing mutant IRs were incubated for 5 min in medium containing 1 \( \mu\text{M} \) insulin, followed by removal of insulin by washing the cells with ice-cold phosphate-buffered saline. Subsequently, cells were lysed, the insulin receptor was immune precipitated, and the immune precipitate was examined by Western blotting for Tyr phosphorylation. As a control experiment, transfected CHO cells expressing a similar level of WT IRs were included. Incubation of cells expressing the WT IR showed a pronounced increase in Tyr phosphorylation of the \( \beta \) subunit, whereas cells expressing Ala\(^{707}\) IR showed no detectable \( \beta \) subunit Tyr phosphorylation (Fig. 7). When the phosphotyrosine phosphatase inhibitor phenyl arsenic oxide was included, no \( \beta \) subunit labeling was detected in the case of Ala\(^{707}\) IR (Fig. 7). Also, when cells were directly lysed in SDS sample buffer after incubation with insulin, Western blot analysis did not show any increase in phosphotyrosine labeling of cellular proteins in the case of the mutant receptor (not shown). These observations argue against a situation in which the mutant receptor is highly susceptible to dephosphorylation by a phosphotyrosine phosphatase.

We also examined insulin-induced receptor autophosphorylation using partially purified insulin receptors, obtained by chromatography on wheat germ agglutinin-Sepharose. Insulin receptors isolated in this way are solubilized in a buffer containing 0.1% Triton X-100. Insulin (1 \( \mu\text{M} \)) was found to induce \( \beta \) chain phosphorylation in the case of WT and mutant receptors. Absolute levels of phosphate incorporation were approximately 15% lower in mutant receptors compared with WT IRs, although this difference did not reach statistical significance. When a dose-response relationship was determined, the \( ED_{50} \) was the same for WT and mutant receptors. The only difference that showed statistical significance was a lower level of phosphate incorporation in mutant receptors at low insulin concentrations (Fig. 8).

To further examine the requirement for Triton X-100 for insulin-induced receptor autophosphorylation and to exclude the possibility that other components of the glycoprotein buffer, such as N-acetylglucosamine, are responsible for the restoration of the interaction between Ala\(^{707}\) IR and insulin, in a parallel experiment we incubated CHO cells expressing WT and mutant IRs for 5 min with insulin. This incubation occurred in an isotonic buffer, containing 1 \( \mu\text{M} \) insulin, ATP, and MnCl\(_2\), reagents required for in vitro autophosphorylation. As a control, cells were incubated in this buffer without insulin. Receptor autophosphorylation was analyzed by lysing the cells by addition of SDS sample buffer, and the lysate was analyzed for the presence of Tyr-phosphorylated proteins by Western

![Fig. 5. The effect of insulin on internalization of insulin receptors.](image)

**TABLE I**

| Cell line     | Binding* |
|---------------|----------|
| Parental CHO  | 2.2 ± 0.2|
| CHO Ala\(^{707}\) IR* | 2.3 ± 0.3|
| CHO WT IR*   | 247 ± 28 |

*Values are mean ± S.D.

**Fig. 6. Cross-linking of \( ^{125}\text{I}-\text{insulin} \) to the insulin receptor \( \alpha \)-subunit.** Glycoprotein was prepared from CHO cells expressing WT or Ala\(^{707}\) IRs. Glycoprotein was incubated with 700 pm \( ^{125}\text{I}-\text{insulin} \) alone (−) or together with 1 \( \mu\text{M} \) nonradioactive insulin (+). Cross-linking to the \( \alpha \) subunit was by disuccinimidyl suberate. Subsequently, proteins were electrophoresed on SDS-polyacrylamide gels and visualized by autoradiography.
Insulin receptor, which replaces Asp707 by Ala. This mutant poration is expressed as percentage of maximum incorporation.

\[
\text{IRs; } \text{a chain, found in patients with leprechaunism or Rabson-Mendenhall syndrome.}
\]

...transported to the cell surface, it is expected that the mutation has no major effect on the overall folding of the α subunit. This situation is corroborated by protein structure predictions, which indicate that substituting Ala for Asp, has no major effect on the probability of the carboxyl terminus adopting an α helical configuration. Because of the smaller side chain of Ala compared with Asp, the helix may become more flexible at that site.

Despite the predicted absence of a major effect on protein folding, Ala707 IR is unable to bind insulin when expressed on cells. The absence of insulin binding to cells expressing the mutant insulin receptor is not the result of enhanced internalization and receptor degradation, a situation seen in the case of the Glu460 mutant (9). We conclude that the loss of insulin binding to cells expressing Ala707 IR is due to a direct effect of the mutation on the process of insulin binding. This loss of binding may, in principle, result from an essential contribution of Asp707 to the interaction of the receptor with insulin or to a conformational change induced by Ala707, which affects the structure of the insulin binding pocket.

When insulin binding to Ala707 IR is determined in the presence of Triton X-100, binding of insulin to the mutant receptor is seen, and this binding induces receptor autophosphorylation. The dose-response relationship for insulin-induced receptor autophosphorylation shows an unchanged ED₅₀ and a slightly, but significantly, lower autophosphorylation at low insulin concentrations. These observations indicate that in the presence of detergent, the mutation has a minor effect on the kinetics of insulin binding and that Asp707 does not provide interactions that are essential for insulin binding. Rather, the data suggest that the introduction of Ala707 induces a change in the positioning of the carboxyl-terminal α helix, which prevents insulin from binding when the receptor is on the cell surface. Detergent somehow is able to insert insulin binding. It may do so by making the structure of the carboxyl-terminal part of the receptor, which is more flexible, thereby allowing the carboxyl terminus of Ala707 IR to adopt a position that allows insulin to bind. Another possibility is that the mutant receptor has gained the ability to bind to another protein, which prevents insulin from binding. We think that this situation is unlikely, because we do not observe coprecipitating proteins in insulin receptor immune precipitates from metabolically labeled Ala707 IR-expressing cells that are absent in cells expressing WT IRs.

Previously, sites on the insulin receptor that are important for the binding of insulin were identified in the NH₂-terminal region, especially Phε₁₈₇ (13–15), the cysteine-rich region (16–18), and the region encoded by exons 6 and 7 (9, 19, 20). Also, an important contribution of Ser³₂³ to the formation of a high affinity insulin binding site on the receptor has been detected by the study of an insulin-resistant patient. Substituting Leu for Ser³₂³ leads to a severe impairment in insulin binding without significantly altering the processing or cell surface expression of the receptor (21).
Subsequently, another site on the receptor has been identified that may contribute to insulin binding. Ultraviolet light-induced cross-linking of B25 azidophenylalanine insulin was found to occur in a peptide comprising residues 704–718 (22). This finding suggests a direct interaction between insulin and the carboxyl terminus of the receptor. Also in agreement with a role of the carboxyl terminus in insulin binding is the observation that a secreted form of the extracellular part of the insulin receptor, in which the carboxyl terminus of the α subunit is lacking, has a low affinity for insulin (23).

The region comprising amino acids 700–718 of the insulin receptor has a high probability to adopt an α helical conformation. As we see a complete loss of insulin binding to the mutant receptor in the absence of detergent, whereas addition of detergent restores binding, it is likely that the precise positioning of the carboxyl terminus is essential to enable binding of insulin. In case of Ala707 IR, this positioning may be somewhat changed, either due to an increased flexibility because of an Ala residue at position 707, or because Asp stabilizes the spatial positioning of the α helix in a conformation that allows binding of insulin. Somehow, detergent is able to restore the correct spatial positioning of the carboxyl terminus of the α chain, thereby restoring the insulin binding site and insulin-induced receptor auto-phosphorylation. Although the precise mechanism by which Ala707 induces a complete loss of insulin binding is not known, our data indicate that the carboxyl terminus of the α subunit provides an essential contribution to the process of insulin binding. Besides, our results show that solubilization by detergent can markedly affect the interpretation of data on mutated receptors when insulin binding characteristics are considered.

Other evidence suggesting a contribution of amino acid residues in the carboxyl terminus of the α subunit to the binding of insulin comes from insulin binding studies of proreceptors. When mutations are present in the tetrabasic processing site at the junction of α and β subunits, proreceptors are generated, which appear on the cell surface (24). It was found that proreceptors without exon 11 have marked reduced insulin binding compared with proreceptors with exon 11, which bind insulin with near normal affinity. Cleavage of proreceptors without exon 11 into α and β subunits markedly restored insulin binding. These findings suggest that the presence or absence of 12 amino acids encoded by exon 11 affects the folding and/or conformation of the α subunit carboxyl-terminal region in the proreceptor to confer altered binding of insulin. In the absence of exon 11, this region is in a strained conformation that disrupts the insulin binding site. Proteolytic cleavage at the α-β junction releases this constraint (25).

After completion of the manuscript, a publication appeared describing alanine-scanning mutagenesis of carboxy-terminal amino acids in the insulin receptor α subunit (26). This study included the replacement of Asp707 by Ala. The results show that when a secreted form of the α subunit is examined for insulin binding, replacement of Asp707 by Ala did not affect insulin binding properties. Replacements of several other amino acid residues in the carboxyl-terminal region by Ala did affect insulin binding. These results support our conclusion that Asp707 as such is not essential for insulin binding when receptors are in the solubilized state. Rather, when the insulin receptor is present on the cell surface, Asp707 is essential in keeping the carboxyl-terminal tail in a spatial conformation, which allows insulin to bind. Ala707 IR represents the first naturally occurring missense mutation in the carboxyl-terminal part of the insulin receptor α subunit that affects binding of insulin in the absence of an effect on receptor processing or transport.

Acknowledgments—We thank Drs. A. Ullrich and R. Lammers for providing the WT IR expression vector and K. Siddle for his generous gift of antibodies against the insulin receptor.

REFERENCES

1. Garvey W. T., and Birnbaum, M. J. (1995) in Bailer’s Clinical Endocrinology and Metabolism (Ferrannini, E., ed) Vol. 7, pp. 785–873, Baillière Tindall, London
2. Ullrich, A., Bell, J. R., Chen, E. Y., Herrera, R., Petruzelli, L. M., Dull, T. J., Gray, A., Coussens, L., Yao, Y., C. Tsuk Kubota, M., Mason, A., Seeburg, P. H., Rosen, O. M., and Ramachandran, J. (1985) Nature 313, 756–761
3. Ebina, Y., Ellis, L., Jarnagin, K., Edery, M., Graf, L., Clauser, E., Ou, J. H., Masarz, F., Kar, Y., Goldfine, I. D., Roth, R. A., and Rutter, W. J. (1985) Cell 40, 747–758
4. Lane, M. D., Ronnett, G., Sileker, L. J., Kohnsari, R. A., and Olson, T. L. (1986) Biochimie (Paris) 67, 1069–1080
5. Taylor, S. i., Cama, A., Aczii, A., Barbetti, F., Quon, M. J., Liu Siera, M., Suzuki, Y., Koller, E., Levy–Tildedano, R., Wertherme, E., Moncada, V. A., Kadowaki, H., and Kadowaki, T. (1992) Endocr. Res. 13, 565–595
6. Muckiss, V. A. (1994) in Mendelian Inheritance in Man (McKusick, V. A., ed) 11th Ed., The Johns Hopkins University Press, Baltimore
7. Van der Vorm, E. R., Van der Zon, G. C. M., Möller, W., Krans, H. M. J., Lindhout, D., and Maassen, J. A. (1990) J. Biol. Chem. 265, 66–71
8. Kadowaki, T., Kadowaki, H., Aczii, D., Yazaki, Y., and Taylor, S. I. (1991) J. Biol. Chem. 266, 21224–21231
9. Kadowaki, H., Kadowaki, T., Cama, A., Marcus–Sanuets, B., Rozvia, A., Boeins, C. and Taylor, S. I. (1990) J. Biol. Chem. 265, 21225–21229
10. Seino, S., Seino, M., and Bell, G. T. (1990) Diabetes 39, 123–128
11. Riedel, H., Dull, T. J., Schlessinger, J., and Ullrich, A. (1990) Nature 346, 68–70
12. Klinkhamer, M. P., Green, N. A., Van der Zon, G. C. M., Lindhout, D., Krans, H. M. J., Möller, W., and Maassen, J. A. (1989) EMBO J. 8, 2503–2507
13. Yip, C. C. (1992) J. Cell. Biochem. 48, 19–25
14. Andersen, A. S., Kjeldsen, T., Wiberg, F. C., Vissing, H., Schaffer, L., Rasmussen, J. S., DeMeyts, P., and Moller, N. P. H. (1992) J. Biol. Chem. 267, 13861–13866
15. DeMeyts, P., Gu, J.-L., Shynko, R. M., Kaplan, B. E., Bell, G. T., and Whittaker, J. (1990) Mol. Endocrinol. 4, 492–416
16. Yip, C. C., Hsu, H., Patel, R. G., Hawley, D. M., Maddux, B. A., and Goldfine, I. D. (1988) Biochem. Biophys. Res. Commun. 157, 321–329
17. Rafaeld, R., Patel, R., Yip, C., Goldfine, I. D., and Hawley, D. M. (1989) J. Biol. Chem. 264, 15900–15904
18. Gustafson, T. A., and Rutter, W. J. (1990) J. Biol. Chem. 265, 18663–18667
19. Fabry, M., Schaffer, E., Ellis, L., Kröp, E., Kahnemadz, F., and Brandenburg, D. (1992) J. Biol. Chem. 267, 8965–8969
20. Zhang, B., and Roth, R. A. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 9858–9862
21. Taus, M., Levy–Tildedano, R., Roach, P., Taylor, S. I., and Gorden, P. (1994) J. Biol. Chem. 269, 14912–14918
22. Kurose, T., Pashmforoush, M., Yoshimasa, Y., Cardi, R., Schwarz, G. P., Burke, G. T., Kato, Katsuyamann, P. G., and Steiner, D. F. (1994) J. Biol. Chem. 269, 29190–29197
23. Schaffer, E. M., Siddle, K., and Ellis, L. (1990) J. Biol. Chem. 265, 13248–13253
24. Yoshimasa, Y., Seino, S., Whitaker, J., Kakehi, T., Kosai, K., Kuzuya, H., Imura, H., Bell, G. T., and Steiner, D. F. (1988) Science 240, 784–787
25. Pashmforoush, M., Yoshimasa, Y., and Steiner, D. F. (1994) J. Biol. Chem. 269, 32639–32648
26. Myna, D. C., Yu, G. Q., and Whittaker, J. (1996) J. Biol. Chem. 271, 2439–2442